Back to search

Article

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based system

2023-09-25

Abstract excerpt

Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL pro /M pro ) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M pro r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d526ecd5-274e-5814-bc41-fe2ef64cd075
DOI
10.1101/2023.09.22.558628
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemDOI 10.1101/2023.09.22.558628
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity
A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity
Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.Semantic proximity
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity
Genetic surveillance of SARS-CoV-2 M <sup>pro</sup> reveals high sequence and structural conservation prior to the introduction of protease inhibitor PaxlovidSemantic proximity
Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain ResistanceSemantic proximity
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity
Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity
Select a neighboring publication to make it the new centre.